The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer.
Int Immunopharmacol
; 121: 110402, 2023 Aug.
Article
em En
| MEDLINE
| ID: mdl-37301125
ABSTRACT
Colorectal cancer is globally ranked second in both incidence and mortality rate. It usually develops during the middle or late stages of diagnosis, and is characterized by easy metastasis, poor prognosis, and a significant decline in postoperative quality of life. ROR1 is an excellent oncoembryonic antigen in numerous immunotherapy treatments for tumors. Additionally, it is overexpressed in colorectal cancer. To fill the void in CRC treatment with ROR1 as a target of CAR-T immunotherapy, we designed and prepared antiROR1-CART. This third-generation CAR-T cell can effectively inhibit the growth of colorectal cancer in vitro and in vivo.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Neoplasias Colorretais
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article